Stockscreener 앱 받기
24.44
3.13%
-0.79
시간 외 거래:
24.54
0.10
+0.41%
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Wedbush Reiterates Arcus Biosciences At Outperform, Sets Price Target Of $43, Casdatifan Data Ahead - RTTNews
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - Yahoo! Finance Canada
RCUS Reiterated by Wedbush -- Price Target Maintained at $43.00 - GuruFocus
Arcus Biosciences, Inc. (RCUS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Gilead Sciences Inc and Arcus Biosciences Inc Post ARC-7 Plenary Q&A Transcript - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance Singapore
Arcus Biosciences stock trades 16.8 percent below yearly high - AD HOC NEWS
(RCUS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
RCUS Looks 292.6% Overvalued on GF Value™ - GuruFocus
Cantor Fitzgerald reiterates Arcus Biosciences stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Arcus Biosciences stock rating - Investing.com
New kidney cancer data from 121 patients will be shared Oct. 20 - Stock Titan
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy - Yahoo Finance
Arcus Biosciences stock holds steady as investors eye latest clinical and earnings signals - AD HOC NEWS
Arcus Biosciences (RCUS) Stock Analysis: Exploring a 51.72% Potential Upside in Biotechnology - DirectorsTalk Interviews
Arcus Biosciences stock gains on TD Cowen buy rating - Investing.com
Arcus Biosciences stock gains on TD Cowen buy rating By Investing.com - Investing.com Canada
Why is Arcus Biosciences stock rallying today? By Investing.com - Investing.com UK
RCUS Initiates Coverage On by TD Cowen -- Rating Set to Buy - GuruFocus
Arcus Biosciences stock initiated at Buy by TD Cowen on RCC drug - Investing.com Australia
TD Cowen Initiates Arcus Biosciences at Buy - marketscreener.com
RCUS: Pivotal ARC-20 data and phase III trials aim to establish casdatifan as a market leader in RCC - TradingView
(RCUS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Arcus Biosciences Slides as Investors Weigh Pipeline Overhang Ahead of Next Data Catalysts - Quiver Quantitative
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Cooper Co (COO) and Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences at cantor global healthcare conference: casdatifan in focus By Investing.com - Investing.com Canada
Arcus Biosciences at cantor global healthcare conference: casdatifan in focus - Investing.com India
One new employee can buy 26,350 Arcus shares. Arcus also awarded rights to 13,200 shares. - Stock Titan
Arcus Biosciences at Citi summit: casdatifan data loom large By Investing.com - Investing.com India
Following VIRO 2025 Success, Arcus Biosciences Continues Partnership in 2026 - oncodaily.com
Truist raises Arcus Biosciences stock price target on trial data By Investing.com - Investing.com South Africa
RCUS Reiterated by Truist Securities -- Price Target Raised to $40 - GuruFocus
RCUS Q2 2026 Earnings: Narrower Loss Beats Estimates by 21.41%Quarterly Financial Update - dars.gov.et
Understanding the Setup: (RCUS) and Scalable Risk - Stock Traders Daily
Arcus Biosciences Inc. (RCUS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arcus Biosciences Inc. (RCUS) Peer Comparison – Compare with Others - Value Research
Arcus Biosciences Inc. (RCUS) Key Financial Ratios – Valuation, Profitability & More - Value Research
Arcus Biosciences Inc. (RCUS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Arcus Biosciences (RCUS) Q1 2025 Earnings: Results, Market Reaction & History - 247wallst.com
Arcus Biosciences will take part in 3 New York conferences in September - Stock Titan
Why Arcus Biosciences (RCUS) Is Getting Attention Today - Sahm
Arcus Biosciences (RCUS) Slides 3.7% as Biotech Sector Volatility PersistsUpthrust Pattern - careplusvn.com
Arcus Biosciences CAO Azoy sells $84,810 in stock By Investing.com - Investing.com Nigeria
Arcus Biosciences CAO Azoy sells $84,810 in stock - Investing.com India
Arcus Biosciences (NASDAQ: RCUS) CAO sells shares from option plan - stocktitan.net
Arcus (RCUS) Range: Rises 2.78% to $30.34 in the Latest Session; Level Watch: Price Remains Between $28.82 Support and $31.86 Resistance on the DayVWAP Bounce - vinanet.vn
Arcus Biosciences (RCUS) officer eyes sale after June plan trades - Stock Titan
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales - Sahm
Investigation launched into Arcus Biosciences o... - Pluang
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm - Morningstar
Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders - webull.com
0.05%
0.82%
자본화:
|
볼륨(24시간):